Holen Sie sich die Stockscreener-App
47.98
2.19%
1.03
Vorhandelsmarkt:
47.31
-0.67
-1.40%
Schlusskurs vom Vortag:
$46.95
Offen:
$47.15
24-Stunden-Volumen:
422.13K
Relative Volume:
1.13
Marktkapitalisierung:
$2.30B
Einnahmen:
$264.38M
Nettoeinkommen (Verlust:
$-109.16M
KGV:
-20.51
EPS:
-2.3395
Netto-Cashflow:
$-39.22M
1W Leistung:
+10.76%
1M Leistung:
+15.59%
6M Leistung:
+21.50%
1J Leistung:
+82.23%
1-Tages-Spanne:
$46.51
$48.66
1-Wochen-Bereich:
$44.15
$48.66
52-Wochen-Spanne:
$23.14
$48.89
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Firmenname
Mirum Pharmaceuticals Inc
Sektor
Branche
Telefon
650-667-4085
Adresse
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Vergleichen Sie MIRM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
47.98 | 2.30B | 264.38M | -109.16M | -39.22M | -2.3395 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-17 | Eingeleitet | Stifel | Buy |
| 2023-12-18 | Bestätigt | H.C. Wainwright | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-11-13 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-09-20 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2021-09-20 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-07 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-25 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-08-12 | Eingeleitet | Citigroup | Buy |
| 2019-08-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-12 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-12 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Mirum Pharmaceuticals Inc Aktie (MIRM) Neueste Nachrichten
Mirum Pharmaceuticals' chief medical officer sells $319,598 in stock By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals' chief medical officer sells $319,598 in stock - MSN
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results - MSN
(MIRM) Investment Report - Stock Traders Daily
Hennion & Walsh Asset Management Inc. Purchases 29,545 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Mirum Pharmaceuticals (MIRM) Is a Great Choice for 'Trend' Investors, Here's Why - MSN
Metagenomi Announces New Appointment to its Board of Directors - The Manila Times
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price Up 6%Here's What Happened - MarketBeat
Mirum Pharmaceuticals exceeds 2024 sales forecast, eyes growth By Investing.com - Investing.com Australia
Mirum Pharmaceuticals exceeds 2024 sales forecast, eyes growth - Investing.com India
Mirum Pharmaceuticals Surpasses 2024 Sales Guidance, Projects Strong 2025 Growth to $435M - StockTitan
This Insider Has Just Sold Shares In Mirum Pharmaceuticals - Simply Wall St
Mirum Pharmaceuticals Grants Stock Awards to Eight New Employees in Growth Initiative - StockTitan
Mirum Pharmaceuticals CEO sells $320,643 in stock - Investing.com India
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Mirum Pharmaceuticals president sells $85,544 in stock By Investing.com - Investing.com Canada
Jolanda Howe Sells 750 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich Sells 1,998 Shares - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz Sells 7,489 Shares - MarketBeat
Mirum pharmaceuticals SVP Jolanda Howe sells shares worth $32,111 By Investing.com - Investing.com Canada
Mirum Pharmaceuticals CEO sells $320,643 in stock By Investing.com - Investing.com Canada
Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3) (MIRM) - Seeking Alpha
Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Analysts Expect Breakeven For Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Before Long - Simply Wall St
(MIRM) Trading Advice - Stock Traders Daily
Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Path To Profitability - Yahoo Finance
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Purchased by Geode Capital Management LLC - Defense World
Geode Capital Management LLC Grows Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Mirum Pharmaceuticals: Buy At Dips For Volixibat Potential (NASDAQ:MIRM) - Seeking Alpha
State Street Corp Buys 297,511 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Brokerages Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Target Price at $57.73 - Defense World
Mirum Pharmaceuticals' SWOT analysis: liver disease specialist's stock poised for growth - Investing.com
Wellington Management Group LLP Has $4.77 Million Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
741,368 Shares in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Bought by Lord Abbett & CO. LLC - MarketBeat
Mirum Pharmaceuticals and GC Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in South Korea - Marketscreener.com
Analysts Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Target Price at $57.73 - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report? - MSN
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 10, 2024 - BioSpace
Frazier Life Sciences Management L.P. Purchases 75,000 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Mirum Pharmaceuticals Awards Key Inducement Grants to Strengthen Leadership Team - StockTitan
Investors Aren't Buying Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Revenues - Simply Wall St
Charles Schwab Investment Management Inc. Acquires 17,149 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Finanzdaten der Mirum Pharmaceuticals Inc-Aktie (MIRM)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):